Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase II drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ifinatamab deruxtecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ifinatamab deruxtecan overview
Ifinatamab deruxtecan (DS-7300) is under development for the treatment of solid tumors including advanced or metastatic head and neck squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, pancreatic ductal adenocarcinoma, metastatic colorectal cancer, metastatic hepatocellular carcinoma, gastric cancer, gastroesophageal junction carcinomas, non-small cell lung cancer, metastatic urothelial carcinoma, esophageal squamous cell carcinoma, squamous and adenocarcinoma of non-small cell lung cancer (NSCLC), small-cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer and breast cancer.
It is also under development for pretreated extensive-stage small cell lung cancer (ES-SCLC). It targets B7-H3/CD276 antigen. The drug candidate is based on antibody drug conjugate (ADC) technology. It is administered through intravenous route as a solution. The drug candidate comprises of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker.
Daiichi Sankyo overview
Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
For a complete picture of Ifinatamab deruxtecan’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
